

**BACLOFEN- baclofen tablet**  
**Chartwell RX, LLC**


-----  
**Baclofen Tablets, USP**

**Rx Only**

**DESCRIPTION**

Baclofen, USP is a muscle relaxant and antispastic.

Its chemical name is 4-amino-3-(4-chlorophenyl)-butanoic acid. The structural formula is:



$C_{10}H_{12}ClNO_2$

M.W. 213.66

Baclofen USP is a white to off-white, odorless or practically odorless crystalline powder. It is slightly soluble in water, very slightly soluble in methanol and insoluble in chloroform.

Each tablet, for oral administration, contains 5 mg, 10 mg or 20 mg baclofen. In addition, each tablet contains the following inactive ingredients: microcrystalline cellulose, pregelatinized starch, colloidal silicon dioxide, and magnesium stearate.

**CLINICAL PHARMACOLOGY**

The precise mechanism of action of baclofen is not fully known. Baclofen is capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Although baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects. In studies with animals baclofen has been shown to have general CNS depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression. Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses. Baclofen is excreted primarily by the kidney in

unchanged form and there is relatively large intersubject variation in absorption and/or elimination.

## **INDICATIONS AND USAGE**

Baclofen tablets are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.

Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

Baclofen tablets are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.

The efficacy of baclofen in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions.

## **CONTRAINDICATIONS**

Hypersensitivity to baclofen.

## **WARNINGS**

a. Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure. If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradually reduce the dose and discontinue baclofen before delivery. If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal.

b. Abrupt Drug Withdrawal: Hallucinations and seizures have occurred on abrupt withdrawal of baclofen. Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued.

c. Impaired Renal Function: Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage.

d. Stroke: Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerability to the drug.

e. Pregnancy: Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams. This abnormality was not seen in mice or rabbits.

There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose. In

mice, no teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose. There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.

## **PRECAUTIONS**

Because of the possibility of sedation, patients should be cautioned regarding the operation of automobiles or other dangerous machinery, and activities made hazardous by decreased alertness. Patients should also be cautioned that the central nervous system effects of baclofen may be additive to those of alcohol and other CNS depressants.

Baclofen should be used with caution where spasticity is utilized to sustain upright posture and balance in locomotion or whenever spasticity is utilized to obtain increased function.

In patients with epilepsy, the clinical state and electroencephalogram should be monitored at regular intervals, since deterioration in seizure control and EEG have been reported occasionally in patients taking baclofen.

It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

A dose-related increase in incidence of ovarian cysts and a less marked increase in enlarged and/or hemorrhagic adrenal glands was observed in female rats treated chronically with baclofen.

Ovarian cysts have been found by palpation in about 4% of the multiple sclerosis patients that were treated with baclofen for up to one year. In most cases these cysts disappeared spontaneously while patients continued to receive the drug. Ovarian cysts are estimated to occur spontaneously in approximately 1% to 5% of the normal female population.

## **Pediatric Use**

Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

## **ADVERSE REACTIONS**

The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%).

Others reported:

Neuropsychiatric: Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred

vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure.

Cardiovascular: Hypotension (0 to 9%). Rare instances of dyspnea, palpitation, chest pain, syncope.

Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool.

Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria.

Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion.

Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.

## **OVERDOSAGE**

Signs and Symptoms: Vomiting, muscular hypotonia, drowsiness, accommodation disorders, coma, respiratory depression and seizures.

Treatment: In the alert patient, empty the stomach promptly by induced emesis followed by lavage. In the obtunded patient, secure the airway with a cuffed endotracheal tube before beginning lavage (do not induce emesis). Maintain adequate respiratory exchange, do not use respiratory stimulants.

## **DOSAGE AND ADMINISTRATION**

The determination of optimal dosage requires individual titration. Start therapy at a low dosage and increase gradually until optimum effect is achieved (usually between 40 to 80 mg daily).

The following dosage titration schedule is suggested:

- 5 mg t.i.d. for 3 days
- 10 mg t.i.d. for 3 days
- 15 mg t.i.d. for 3 days
- 20 mg t.i.d. for 3 days

Thereafter additional increases may be necessary but the total daily dose should not exceed a maximum of 80 mg daily (20 mg q.i.d.).

The lowest dose compatible with an optimal response is recommended. If benefits are not evident after a reasonable trial period, patients should be slowly withdrawn from the drug (see **WARNINGS**, Abrupt Drug Withdrawal).

## **HOW SUPPLIED**

Baclofen Tablets USP, 5 mg are available as a white round convex tablet debossed with "LCI" on one side and "1333" on the other side. Available in bottles of 90 (NDC 62135-

472-90).

Baclofen Tablets USP, 10 mg are available as a white round flat-faced beveled edge bisected tablet debossed with "LCI" over "1330" on one side and plain on the other side, containing 10 mg Baclofen USP. Available in bottles of 90 (NDC 62135-473-90) and 500 (NDC 62135-473-05).

Baclofen Tablets USP, 20 mg are available as a white round flat-faced beveled edge bisected tablet debossed with "LCI" over "1337" on one side and plain on the other side, containing 20 mg Baclofen USP. Available in bottles of 90 (NDC 62135-474-90) and 500 (NDC 62135-474-05).

PHARMACIST: Dispense in a well-closed container as defined in the USP, with a child-resistant closure (as required).

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Manufactured for:  
Chartwell RX, LLC.  
Congers, NY 10920

L71279  
Rev. 02/2023

## PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

### Baclofen Tablets, USP 5 mg- NDC 62135-472-90 - 90s-bottle label

NDC 62135-472-90

# Baclofen Tablets, USP

**5 mg**

Rx Only  
90 Tablets

Chartwell Rx

Each tablet contains:  
5 mg of Baclofen, USP

**USUAL DOSAGE:**  
See package insert for complete prescribing information.  
Dispense in a well-closed container as defined in the USP  
with a child-resistant closure.  
Store at 20° to 25°C (68° to 77°F) [See USP Controlled  
Room Temperature].

**KEEP THIS AND ALL MEDICATION OUT OF THE  
REACH OF CHILDREN.**

This bottle has been sealed for your protection.

Manufactured For: Chartwell RX, LLC.  
Congers, NY 10920

GTIN 00362135472900 L71274 REV. 01 02/23

3 62135 47290 0

No Varnish

### Baclofen Tablets, USP 10 mg- NDC 62135-473-90 - 90s-bottle label

NDC 62135-473-90

# Baclofen Tablets, USP

10 mg

Rx Only  
90 Tablets

Chartwell Rx

Each tablet contains:  
10 mg of Baclofen, USP

**USUAL DOSAGE:**

See package insert for complete prescribing information.  
Dispense in a well-closed container as defined in the USP with a child-resistant closure.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

**KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.**

This bottle has been sealed for your protection.

Manufactured For: Chartwell RX, LLC.  
Congers, NY 10920

GTIN 00362135473907 L71275 REV. 01 02/23



No Varnish

Baclofen Tablets, USP 10 mg- NDC 62135-473-05 - 500s-bottle label

NDC 62135-473-05

# Baclofen Tablets, USP

10 mg

Rx Only  
500 Tablets

Chartwell Rx

Each tablet contains:  
10 mg of Baclofen, USP

**USUAL DOSAGE:**

See package insert for complete prescribing information.  
Dispense in a well-closed container as defined in the USP with a child-resistant closure.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

**KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.**

This bottle has been sealed for your protection.

Manufactured For: Chartwell RX, LLC.  
Congers, NY 10920

GTIN 00362135473051 L71276 REV. 01 02/23



No Varnish

Baclofen Tablets, USP 20 mg- NDC 62135-474-90 - 90s-bottle label

NDC 62135-474-90

# Baclofen Tablets, USP

**20 mg**

Rx Only  
90 Tablets

Chartwell Rx

Each tablet contains:  
20 mg of Baclofen, USP

**USUAL DOSAGE:**  
See package insert for complete prescribing information.  
Dispense in a well-closed container as defined in the USP with a child-resistant closure.  
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

**KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.**

This bottle has been sealed for your protection.  
Manufactured For: Chartwell RX, LLC.  
Congers, NY 10920

GTIN 00362135474904 L71277 REV. 01 02/23



N 3 62135 47490 4

No Varnish

Baclofen Tablets, USP 20 mg- NDC 62135-474-05 - 500s-bottle label

NDC 62135-474-05

# Baclofen Tablets, USP

**20 mg**

Rx Only  
500 Tablets

Chartwell Rx

Each tablet contains:  
20 mg of Baclofen, USP

**USUAL DOSAGE:**  
See package insert for complete prescribing information.  
Dispense in a well-closed container as defined in the USP with a child-resistant closure.  
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

**KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.**

This bottle has been sealed for your protection.  
Manufactured For: Chartwell RX, LLC.  
Congers, NY 10920

GTIN 00362135474058 L71278 REV. 01 02/23



N 3 62135 47405 8

No Varnish

## BACLOFEN

baclofen tablet

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:62135-472
Route of Administration	ORAL		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
BACLOFEN (UNII: H789N3FKE8) (BACLOFEN - UNII:H789N3FKE8)	BACLOFEN	5 mg

**Inactive Ingredients**

Ingredient Name	Strength
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STARCH, CORN (UNII: O8232NY3SJ)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	

**Product Characteristics**

Color	white	Score	no score
Shape	ROUND	Size	6mm
Flavor		Imprint Code	LCI;1333
Contains			

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:62135-472-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	03/03/2023	

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA077241	09/22/2021	

**BACLOFEN**

baclofen tablet

**Product Information**

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:62135-473
Route of Administration	ORAL		

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
BACLOFEN (UNII: H789N3FKE8) (BACLOFEN - UNII:H789N3FKE8)	BACLOFEN	10 mg

## Inactive Ingredients

Ingredient Name	Strength
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STARCH, CORN (UNII: O8232NY3SJ)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	

## Product Characteristics

Color	white	Score	2 pieces
Shape	ROUND	Size	9mm
Flavor		Imprint Code	LCI;1330
Contains			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:62135-473-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	03/03/2023	
2	NDC:62135-473-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	03/03/2023	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA077241	07/01/2007	

## BACLOFEN

baclofen tablet

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:62135-474
Route of Administration	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BACLOFEN (UNII: H789N3FKE8) (BACLOFEN - UNII:H789N3FKE8)	BACLOFEN	20 mg

## Inactive Ingredients

Ingredient Name	Strength
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STARCH, CORN (UNII: O8232NY3SJ)	

<b>SILICON DIOXIDE</b> (UNII: ETJ7Z6XBU4)	
<b>MAGNESIUM STEARATE</b> (UNII: 70097M6I30)	

### Product Characteristics

<b>Color</b>	white	<b>Score</b>	2 pieces
<b>Shape</b>	ROUND	<b>Size</b>	10mm
<b>Flavor</b>		<b>Imprint Code</b>	LCI;1337
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:62135-474-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	03/03/2023	
2	NDC:62135-474-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	03/03/2023	

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA077241	12/20/2005	

**Labeler** - Chartwell RX, LLC (079394054)

Revised: 10/2024

Chartwell RX, LLC